VIR
Vir Biotechnology, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 23 to Mar 2 ▼ 4 days of insider sells: $1.2M by 6 insiders, avg $9.17
- Mar 23 ▼ 1 insider sell $70.3K at $9.12
- Apr 1 to Apr 6 ▼ 2 days of insider sells: $864.0K by 2 insiders, avg $9.14
- May 1 ▼ 1 insider sell $221.0K at $10.05
- Jun 1 ▼ 2 insiders sell $33.8K at $9.45
- Aug 14 Smith v. Vir Biotechnology, Inc.
- Sep 23 Smith v. Vir Biotechnology, Inc.
- Oct 14 ▲ Vir Biotechnology entered into a collaboration and license agreement…
- Oct 21 Trial readout: Results Pending: BRII-179 (Phase 2), Completed 77d ago
- Nov 2 to Nov 3 ▼ 2 days of insider sells: $41.9K by 1 insider, avg $11.18
- Nov 4 ▲ Earnings: VIR Q3 2026 Earnings: EPS $-0.57 (+25.2% vs est)
- Nov 9 ▲ Vir Biotechnology announced positive Phase 3 ECLIPSE 1 topline resul…
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $2.4M.
- InstitutionsBEARISH
Q3 2026: 9 added (0 new), 21 trimmed or exited.
- AnalystsBULLISH
12 of 13 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.647 → −$0.063 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +3.9% to 16.87M shares. 11.9 days to cover, ≈9.8% of shares.
- TrendRANGE
14% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | TRIM | $7.2M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $4.4M |
| Ensign Peak Advisors, Inc | TRIM | $4.4M |
| UBS Group AG | TRIM | $2.8M |
| SEI INVESTMENTS CO | ADD | $1.8M |
| Russell Investments Group, Ltd. | ADD | $1.5M |
| VANGUARD ASSET MANAGEMENT, Ltd | ADD | $1.1M |
| Jump Financial, LLC | NEAR_EXIT | $972.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is below the lowest target. Median implies +140%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 10, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Nov 9, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Nov 9, 2026 | Needham MAINTAIN | Buy |
| Nov 5, 2026 | Needham MAINTAIN | Buy |
| Oct 7, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 15, 2026 | AWARD | |
| 🔒 Fresh data, subscribers only Nov 15, 2026 | AWARD | |
| 🔒 Fresh data, subscribers only Nov 15, 2026 | AWARD | |
de Verneuil Vanina EVP, General Counsel, Corp Sec Nov 3, 2026 | SELL | $26.7K |
de Verneuil Vanina EVP, General Counsel, Corp Sec Nov 2, 2026 | SELL | $15.2K |
Topalian Suzanne Louise Director Oct 27, 2026 | AWARD | 9,462 sh |
Topalian Suzanne Louise Director Oct 27, 2026 | AWARD | 16,000 sh |
Topalian Suzanne Louise Director Oct 27, 2026 | AWARD | 4,731 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.06 | -$0.68–$0.77 | +90.0% | $87.4M |
| Next Q | -$0.44 | -$0.66–-$0.31 | -3.9% | $17.0M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
36 filings · 3 bullish · 8 bearish · 25 neutral- BEARISH 424B5Nov 16, 2026
Vir Biotechnology priced an underwritten public offering of 17,250,000 shares of common stock (including the underwriters' option to purchase 2,250,000 shares) at $10.00 per share, for a maximum aggregate offering price of $172.5 million. The offering is a takedown from the company's automatic…
🔒 Fresh report (last 24h), subscribers only
- BEARISH 8-KNov 13, 2026
Vir Biotechnology priced an underwritten public offering of 15,000,000 shares of common stock at…
Monitor the company's upcoming quarterly results for cash burn rate and progress on CHD program pre-commercial activities; the activist stake reduction one week prior suggests insider selling ahead…
- BEARISH 424B5Nov 12, 2026
Vir Biotechnology filed a preliminary prospectus supplement for an underwritten public offering of…
Monitor the final pricing and share count when the supplement is completed. The offering size relative to market cap will determine the degree of dilution. The company's cash runway extends into H2…
- NEUTRAL S-3ASRNov 12, 2026
Vir Biotechnology filed an automatic shelf registration (S-3ASR) to register an unlimited amount…
Monitor for a prospectus supplement that would disclose actual offering size, terms, and use of proceeds. The strong cash position and recent Gilead deal suggest any future draw would likely be…
All VIR filing & press-release reports (36)
- 424B5 reportNov 16, 2026
- 8-K reportNov 13, 2026
- 424B5 reportNov 12, 2026
- S-3ASR reportNov 12, 2026
- SC 13G reportNov 10, 2026
- 8-K reportNov 9, 2026
- SC 13D/A reportNov 6, 2026
- 8-K reportNov 4, 2026
- 144 reportNov 3, 2026
- 144 reportNov 2, 2026
- 3 reportOct 28, 2026
- 8-K reportOct 28, 2026
- SC 13G/A reportOct 27, 2026
- 8-K reportOct 14, 2026
- 8-K reportOct 8, 2026
- 3 reportOct 6, 2026
- 8-K reportOct 1, 2026
- COURT-RULING reportSep 23, 2026
- COURT-RULING reportAug 14, 2026
- INST-CLUSTER reportAug 9, 2026
- 8-K reportJul 24, 2026
- 144 reportJun 29, 2026
- 3 reportJun 10, 2026
- 8-K reportJun 10, 2026
- CLUSTER reportJun 2, 2026
- 8-K reportMay 28, 2026
- DEFA14A reportApr 16, 2026
- 8-K reportApr 10, 2026
- CLUSTER reportApr 1, 2026
- 8-K reportMar 4, 2026
- CLUSTER reportFeb 24, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026